Wells Fargo Initiates Coverage On NewAmsterdam Pharma Co with Overweight Rating, Announces Price Target of $45
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
Wells Fargo analyst Yanan Zhu initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Overweight rating and announces Price Target of $45.
Wells Fargo analyst Yanan Zhu initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Overweight rating and announces Price Target of $45.